Promotie onderzoek

The landscape of drug development as well as clinical practice has been changing  over the last decennium, with the increasing availability and use of biobased therapies. This research is now focusing on the use and therapeutic drug monitoring of biobased factor VIII therapies in hemophilia A patients.

• A prospective observational PK/PD to study the target attainment for β-lactam antibiotics in critical ill patients and its associated risk factors.
• A multi-centre, randomised controlled trial to assess the efficacy and cost-effectiveness of model-based TDM of beta-lactam and fluoroquinolone antibiotics.

1. Optimasation of the flucloxacillin absorptiontest.
2. PK modeeling of cefotaxim in critically ill patients.
3. PK modeling of flucloxacillin in mice.

Part 1: Optimizing ribavirin therapy in transplant recipients with a chronic hepatitis E virus infection by devoloping a NONMEM model for ribavirin. Part 2: Improving immunosuppressive therapy in liver transplant recipients by performing 2 RCT's in which different immunosuppresive strategies will be compared to modify the tacrolimus related toxicity in this population. Part 3: Evaluate the contribution of an outpatient medication service for liver transplant recipients.

1. To study the impact of inflammation on midazolam pharmacokinetics in critically ill covid-19 patients.
2. To study the impact of continuous renal replacement therapy on target attainment and pharmacokinetics of drugs in critically ill patients.

Het onderzoeken van PK/PD relaties middels farmacometrische modellen en de implicaties daarvan op de dagelijkse klinische praktijk op de afdeling oncologie.